Allergan's second-quarter revenues were down by 0.8 percent to $4,090 million, but increased by 1.2 percent on a currency-neutral basis. The operating loss widened to $1,263 million from $467.0 million a year earlier due to impairment charges. On an adjusted basis, the group posted operating income of $1,850 million, down by 6.3 percent. Allergan, which is due to be taken over by the U.S. biopharmaceutical group AbbVie, raised its full-year sales guidance to a range of $15.4 billion to 15.6 billion.